UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

December 39, 2019

Date of Report (Date of earliest event reported)

Sophiris Bio Inc.
(Exact name of registrant as specified in its charter)
British Columbia	001-36054	98-1008712
(State or other jurisdiction	(Commission File Number)	(IRS Employer Identification No.)
of incorporation)

Sophiris Bio Inc.
(Exact name of registrant as specified in its charter)

1258 Prospect Street La Jolla, CA		92037
British Columbia	001-36054		98-1008712
(Address of principal executive offices)		(Zip Code)
(State or other jurisdiction	(Commission File Number)		(IRS Employer Identification No.)
of incorporation)

Registrant’s telephone number, including area code: (858) 777-1760

1258 Prospect Street La Jolla, CA	92037
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (858) 777-1760

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value	SPHS	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 35.0102 ~~Notice~~Departure of ~~Delisting~~Directors or ~~Failure~~Certain toOfficers; ~~Satisfy~~Election aof ~~Continued~~Directors; ~~Listing~~Appointment ~~Rule~~of orCertain ~~Standard~~Officers; ~~Transfer~~Compensatory Arrangements of ~~Listing~~Certain Officers.

On ~~June~~December 49, 2019, ~~Sophiris Bio Inc~~Dr. ~~(the~~Allison ~~“Company”)~~Hulme ~~received~~tendered aher ~~letter~~resignation ~~from~~as ~~the~~Chief ~~Listing~~Operating ~~Qualifications~~Officer ~~Department~~and Head of ~~The~~Research ~~Nasdaq~~and ~~Stock~~Development ~~Market~~to ~~(“Nasdaq”)~~pursue ~~notifying~~another ~~the~~business ~~Company~~opportunity. ~~that~~Dr. ~~the closing bid price of the Company~~Hulme’s ~~common~~resignation ~~shares~~will ~~had~~be ~~been~~effective ~~below~~December $131, 2019.00 ~~per~~Dr. ~~share~~Hulme ~~for~~will 30remain ~~consecutive business days and that the Company was therefore not~~ in ~~compliance~~her ~~with~~position ~~the minimum bid price requirement for continued listing on The Nasdaq Capital Market,~~ as ~~set~~a ~~forth~~director inof ~~Marketplace~~the ~~Rule 5550(a)(2)~~Company.

~~Nasdaq~~Effective ~~stated~~January in1, ~~its~~2020, ~~June~~the ~~4th~~Company ~~letter~~and ~~that,~~Dr. inHulme ~~accordance~~plan ~~with~~to ~~Marketplace~~enter ~~Rule~~into ~~5810(c)(3)(A),~~a ~~the~~consulting ~~Company~~agreement ~~had~~under ~~been~~which ~~provided~~Dr. aHulme ~~grace~~will ~~period~~provide ofcertain ~~180~~services ~~calendar~~to ~~days~~the Company, orincluding ~~until~~services ~~December~~related 2,to ~~2019,~~investor toand ~~regain~~partnering ~~compliance~~discussions ~~with~~and the ~~minimum~~Company’s ~~closing~~development ~~bid~~and ~~price~~regulatory ~~requirement~~program ~~for~~and ~~continued listing~~strategies.

OnEffective ~~December~~January 31, ~~2019~~2020, ~~the~~Dr. ~~Company~~Hulme ~~received~~will abegin ~~letter~~to ~~from~~receive ~~the~~compensation ~~Nasdaq~~under ~~which noted that~~ the Company’s ~~had~~Non-Employee ~~not~~Director ~~regained~~Compensation ~~compliance with the closing bid price requirement as of December 2, 2019~~Plan. AtAs ~~this~~permitted ~~point~~under ~~in time,~~ the Company’s ~~does~~2011 ~~not~~Stock ~~qualify~~Option ~~for~~Plan, aDr. ~~second~~Hulme's ~~180-day~~outstanding ~~period~~options towill ~~regain~~remain ~~compliance~~in ~~with~~place ~~the $1.00 closing bid price requirement~~ and ~~therefore~~the ~~this~~options ~~deficiency~~will ~~serves~~continue asto anvest ~~additional~~in ~~basis~~accordance ~~for~~with ~~delisting of~~ the ~~Company’s~~original ~~securities~~option awards.

The Company has until December 10, 2019 to presents its views with respect to this additional deficiency to the Nasdaq Hearings Plan. The notification from Nasdaq does not have an immediate effect on the listing of the Company’s common shares and the Company’s common shares will continue to trade on The Nasdaq Capital Market under the symbol "SPHS".

The Company is considering actions that it may take in response to this notification in order to regain compliance with the continued listing requirements including but not limited to a potential reverse stock.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Sophiris Bio Inc.
Dated: December 9, 2019
Dated: December 13, 2019
	By:	/s/ Peter Slover
		Peter Slover
		Chief Financial Officer

Filing Compare · SOPHIRIS BIO INC.